Lung Cancer Dispatch
Follow
Find tag "ImmunoGen"
4.0K views | +0 today
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Clinical Trial of New SCLC Drug Enrolling Patients

Clinical Trial of New SCLC Drug Enrolling Patients | Lung Cancer Dispatch | Scoop.it

A clinical trial at six study sites, including Smilow Cancer Hospital at Yale-New Haven, will investigate a new treatment for small cell lung cancer (SCLC). IMGN901 (lorvotuzumab mertansine), produced by ImmunoGen, is a novel type of treatment that targets CD56, a protein that is expressed by tumors in a number of different cancers, including SCLC. Because IMGN901 specifically targets a tumor protein, the toxic drug is delivered preferentially to cancer cells and is less likely to harm healthy cells. Another drug using a similar mechanism was recently approved for breast cancer.


To find out more about the trial, call 203-200-5864.

ImmunoGen page on IMGN901: http://www.immunogen.com/pipeline/lorvotuzumab-mertansine/

Cancer Commons's insight:

New Haven Register | Mar 2, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Pilot Study of New SCLC Drug Offers Encouragement

Preliminary trial results indicate that a new drug, IMGN901, enhances standard etoposide/carboplatin treatment in some small cell lung cancer (SCLC) patients. IMGN901 targets cells that express the protein CD56—a hallmark of nearly all SCLC tumors. ImmunoGen, Inc. will further investigate the SCLC treatment potential of IMGN901 in the large-scale NORTH trial.

Cancer Commons's insight:

equities.com | Sep 11, 2012

more...
No comment yet.